Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial f
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
09:00am, Wednesday, 27'th Nov 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
02:40pm, Monday, 25'th Nov 2024
The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 O
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
10:06am, Saturday, 09'th Nov 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
07:26am, Friday, 18'th Oct 2024
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
03:06pm, Thursday, 03'rd Oct 2024
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) brea
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
11:42am, Monday, 16'th Sep 2024
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
08:30am, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
09:02am, Friday, 09'th Aug 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee -
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
07:00pm, Thursday, 18'th Jul 2024
NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) br
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
03:32pm, Wednesday, 10'th Jul 2024
Amylyx Pharmaceuticals Inc AMLX acquired avexitide from Eiger BioPharmaceuticals Inc EIGRQ for $35.1 million.
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
02:23pm, Wednesday, 10'th Jul 2024
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Kle
This cheap biotech offers investors a play on ALS if trial data continues to impress
12:34pm, Tuesday, 02'nd Jul 2024
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
03:35pm, Tuesday, 25'th Jun 2024
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initia
